BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 23335022)

  • 1. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.
    Samama MM; Guinet C; Le Flem L; Ninin E; Debue JM
    J Thromb Thrombolysis; 2013 Feb; 35(2):140-6. PubMed ID: 23335022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
    Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
    Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacologic heterogeneity of new anticoagulants].
    Samamaa MM; Conard J; Flaujac C; Combe S; Horellou MH
    J Mal Vasc; 2011 Dec; 36 Suppl 1():S10-5. PubMed ID: 22177763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.
    Helin TA; Pakkanen A; Lassila R; Joutsi-Korhonen L
    Clin Chem; 2013 May; 59(5):807-14. PubMed ID: 23378569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New anticoagulants as thromboprophylaxis after total hip or knee replacement.
    Hamidi V; Ringerike T; Hagen G; Reikvam Å; Klemp M
    Int J Technol Assess Health Care; 2013 Jul; 29(3):234-43. PubMed ID: 23768996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement.
    Freyburger G; Macouillard G; Labrouche S; Sztark F
    Thromb Res; 2011 May; 127(5):457-65. PubMed ID: 21277622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
    Loke YK; Kwok CS
    J Clin Pharm Ther; 2011 Feb; 36(1):111-24. PubMed ID: 21198726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
    Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
    Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.
    Gómez-Outes A; Terleira-Fernández AI; Suárez-Gea ML; Vargas-Castrillón E
    BMJ; 2012 Jun; 344():e3675. PubMed ID: 22700784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
    Lereun C; Wells P; Diamantopoulos A; Rasul F; Lees M; Sengupta N
    J Med Econ; 2011; 14(2):238-44. PubMed ID: 21385145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
    McCullagh L; Tilson L; Walsh C; Barry M
    Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
    Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
    Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
    Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M
    Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
    Schellings MW; Boonen K; Schmitz EM; Jonkers F; van den Heuvel DJ; Besselaar A; Hendriks JG; van de Kerkhof D
    Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters.
    Green L; Lawrie AS; Patel R; Stephens RC; Mackie IJ; Chitolie A; Haddad FS; Machin SJ
    Thromb Res; 2012 Nov; 130(5):775-9. PubMed ID: 22245224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
    Cohen A; Drost P; Marchant N; Mitchell S; Orme M; Rublee D; Simon TA; Sutton A
    Clin Appl Thromb Hemost; 2012 Nov; 18(6):611-27. PubMed ID: 22387582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
    Graff J; Harder S
    Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
    Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
    Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
    Marlu R; Hodaj E; Paris A; Albaladejo P; Cracowski JL; Pernod G
    Thromb Haemost; 2012 Aug; 108(2):217-24. PubMed ID: 22627883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.